A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)
Phase of Trial: Phase I
Latest Information Update: 27 Dec 2016
Price : $35 *
At a glance
- Drugs Enoblituzumab (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics
- Sponsors MacroGenics
- 21 Dec 2016 Status changed from recruiting to discontinued as Unable to accrue as planned for optional biopsies.
- 05 Nov 2014 Planned End Date changed from 1 Mar 2014 to 1 Feb 2016 according to ClinicalTrials.gov record.
- 05 Nov 2014 Planned primary completion date changed from 1 Mar 2014 to 1 Feb 2016 according to ClinicalTrials.gov record.